Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Vratizolin is a new non-steroidal anti-inflammatory drug registered for use on humans in Poland. Published and unpublished data on Vratizolin showed that it has anti-inflammatory, antiviral, antibacterial, antimycotic, analgesic and immunomodulating activities. The purpose of these randomized, parallel-group studies was to compare Vratizolin with other standard drugs, used for the treatment of mouth and ear infections. The study involved 193 patients with recurrent Herpes simplex, Herpes zoster oticus, Stomatitis herpetica and infections of the external ear canal. Vratizolin was used topically, as 3% hydrophilic cream or ointment, four times daily. Standard treatment included zinc ointment, Aphtin (boric acid plus glycerin), Oxycort and Dicortinef. In almost all of the treated patients the efficacy of Vratizolin treatment was superior to the drugs mentioned above. It was assessed by measuring disappearance of both objective (edema, erythema, crusting) and subjective symptoms (pain, burning and itching).
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!